About us Contacts Drug interactions: 390 212
Drug search by name

Equetro and Lamictal (Lamotrigine Chewable Dispersible Tablets)

Determining the interaction of Equetro and Lamictal (Lamotrigine Chewable Dispersible Tablets) and the possibility of their joint administration.

Check result:
Equetro <> Lamictal (Lamotrigine Chewable Dispersible Tablets)
Relevance: 23.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Before using carBAMazepine, tell your doctor if you also use lamoTRIgine. This combination may cause restlessness, seizures, tremors, slurred speech, staggering walk, and feeling light-headed or fainting. If you take both medications together, tell your doctor if you have any of these symptoms. You may need a dose adjustment or special tests in order to safely take both medications together. Avoid driving until you know how the medications will affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Coadministration with carbamazepine may decrease the serum concentrations of lamotrigine. The mechanism is carbamazepine induction of the hepatic glucuronidation of lamotrigine. Studies have found that carbamazepine can reduce lamotrigine serum concentrations by approximately 40%, and there have been case reports of patients who developed significantly increased lamotrigine levels and/or lamotrigine toxicity following withdrawal of carbamazepine.

MONITOR: Lamotrigine has been reported to enhance the toxicity of carbamazepine by increasing the plasma concentrations of the pharmacologically active epoxide metabolite of carbamazepine, although data are conflicting. In one report, mean serum carbamazepine-10,11-epoxide concentration increased by 45% and the carbamazepine-10,11-epoxide to carbamazepine ratio increased by 19% in nine patients following the introduction of lamotrigine. Four of the patients also experienced symptoms of clinical toxicity during the combination. Other investigators have failed to find evidence of a pharmacokinetic interaction in either children or adults. However, toxicity has occurred in the absence of significant alterations in carbamazepine or carbamazepine-10,11-epoxide pharmacokinetics, suggesting the possibility of a pharmacodynamic interaction. One study found that toxicity is more likely to occur if the initial carbamazepine level is high (above 8 mg/L in study patients) upon lamotrigine introduction.

MANAGEMENT: When lamotrigine is added to existing therapy containing carbamazepine without valproate, the initial dosage of lamotrigine should be 0.6 mg/kg/day in two divided doses (2 to 12 years of age) or 50 mg/day (older than 12 years of age) for the first 2 weeks. The initial dosage should be doubled for the next 2 weeks, then increased by 1.2 mg/kg/day or 100 mg/day every 1 to 2 weeks as needed and as tolerated. The usual maintenance dosage is 5 to 15 mg/kg/day (up to 400 mg/day) in children up to 12 years of age and 300 to 500 mg/day (400 mg/day for the treatment of bipolar disorder) in older patients. Patients should be advised to promptly notify their physician if they experience worsening of seizure control, increased adverse effects, or signs of carbamazepine toxicity such as dizziness, drowsiness, vertigo, diplopia, nystagmus, ataxia, and nausea. A reduction in carbamazepine dosage generally will resolve the toxicity without the need to discontinue either drug. However, a reevaluation of all antiepileptic agents in the regimen should be considered prior to making any changes. If carbamazepine is discontinued, lamotrigine half-life will be prolonged and a dosage adjustment may be necessary. Prescribers should refer to the lamotrigine product labeling for complete dosing information.

References
  • Jawad S, Richens A, Goodwin G, Yuen WC "Controlled trial of lamotrigine (Lamictal) for refractory partial seizures." Epilepsia 30 (1989): 356-63
  • Bottiger Y, Svensson JO, Stahle L "Lamotrigine drug interactions in a TDM material." Ther Drug Monit 21 (1999): 171-4
  • Patsalos PN, Perucca E "Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs." Lancet Neurol 2 (2003): 473-81
  • Reimers A, Skogvoll E, Sund JK, Spigset O "Drug Interactions Between Lamotrigine and Psychoactive Drugs: Evidence From a Therapeutic Drug Monitoring Service." J Clin Psychopharmacol 25 (2005): 342-348
  • Spina E, Pisani F, Perucca E "Clinically significant pharmacokinetic drug interactions with carbamazepine - an update." Clin Pharmacokinet 31 (1996): 198-214
  • Subuh Surja AA, Brotzge KE, El-Mallakh RS "Serious rash with lamotrigine after carbamazepine discontinuation: a case report." J Clin Psychiatry 66 (2005): 400-401
  • Pisani F, Xiao B, Fazio A, Spina E, Perucca E, Tomson T "Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy." Epilepsy Res 19 (1994): 245-8
  • Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS "Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide." Epilepsy Res 11 (1992): 147-50
  • Koch HJ, Szecsey A, Vogel M "Clinically relevant reduction of lamotrigine concentrations by carbamazepine." Eur Psychiatry 18 (2003): 42
  • Patsalos PN, Froscher W, Pisani F, van Rijn CM "The importance of drug interactions in epilepsy therapy." Epilepsia 43 (2002): 365-385
  • "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome, Research Triangle Park, NC.
  • Vauzelle-Kervroedan F, Rey E, Cieuta C, et al. "Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children." Br J Clin Pharmacol 41 (1996): 325-30
  • Eriksson AS, Hoppu K, Nergardh A, Boreus L "Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy." Epilepsia 37 (1996): 769-73
Equetro

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: n.a.

Lamictal (Lamotrigine Chewable Dispersible Tablets)

Generic Name: lamotrigine

Brand name: Lamictal, Lamictal ODT, Lamictal XR, Lamictal, Lamictal ODT, Lamictal XR, Subvenite, Lamictal CD, LaMICtal Starter Kit, LaMICtal ODT Patient Titration Kit, LaMICtal XR Patient Titration Kit, LamoTRIgine Starter Kit, Subvenite Starter Kit

Synonyms: Lamictal

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.